Micafungin Pharmline

Micafungin, the active ingredient in Micafungin Pharmline, is an echinocandin presented as an intravenous solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis and provides prophylaxis against Candida infections in patients undergoing hematopoietic stem‑cell transplantation, as well as off‑label use for invasive aspergillosis in immunocompromised individuals.

GNH USA supplies Micafungin Pharmline as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal that interferes with the fungal cell wall synthesis, making it effective for several serious fungal infections.

- Invasive candidiasis: treatment of bloodstream and deep‑tissue Candida infections in adults. - Esophageal candidiasis: eradication of Candida infection of the esophagus, especially in immunocompromised patients. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevention of invasive candidiasis during the high‑risk transplant period. - Invasive aspergillosis (off‑label): adjunctive therapy for severe aspergillus infections when other options are limited.

Micafungin may cause a range of adverse reactions, from mild to severe. Monitoring during therapy is recommended.

Common Side Effects: - Fever: transient elevation of body temperature during infusion. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate headache. - Phlebitis: irritation at the infusion site. - Elevated liver enzymes: mild, reversible transaminase increase. - Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects: - Hepatic failure: signs of severe liver injury requiring immediate discontinuation. - Severe hypersensitivity: including anaphylaxis, bronchospasm, or angioedema. - Renal impairment: acute kidney injury in susceptible patients. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare severe skin reactions. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Cardiac arrhythmias: rare reports of QT prolongation.

Before initiating Micafungin therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters. - Renal function: evaluate baseline creatinine and monitor during treatment. - Hepatic function: check liver enzymes before and periodically throughout therapy. - Pregnancy and lactation: use only if potential benefit justifies the risk to the fetus or infant. - Concomitant medications: review for possible drug‑drug interactions that may alter micafungin exposure. - Infusion monitoring: administer under medical supervision and observe for infusion‑related reactions. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several agents that affect its metabolism or increase toxicity risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase micafungin plasma concentrations. - Rifampin or other potent CYP3A4 inducers: can substantially reduce micafungin exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Cyclosporine: may increase micafungin levels; monitor cyclosporine troughs. - Tacrolimus: potential increase in tacrolimus exposure; adjust dose as needed. - Warfarin: monitor INR closely due to possible alteration of anticoagulant effect. - Fluconazole: may modestly raise micafungin concentrations; observe for toxicity.